Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Neuropharmacology. 2020 Jan 24;167:107949. doi: 10.1016/j.neuropharm.2020.107949

Fig. 5. Lorcaserin preferentially accumulates in the CNS relative to plasma upon subcutaneous administration.

Fig. 5.

(A) Brain, spinal cord, and plasma concentrations of lorcaserin 30 and 120 min after a single administration (s.c., 2 mg/kg) (n = 5–10). Tissue, F[2,44] = 140, p < 0.001; time, F[1,44] = 107, p < 0.001; interaction of tissue and time, F[2,44] = 28.71, p < 0.001. (B) Brain concentrations of oxycodone after a single dose of oxycodone (o.g., 10 mg/kg) alone, or together with lorcaserin (s.c., 2 mg/kg) (n = 6–10). Drug F[1,28] = 0.75, p >0.05 ; time, F[1,28] = 5.91, p < 0.05; interaction of drug and time, F[1,28] = 0.62, p >0.05. (C) Plasma concentrations of oxycodone after a single dose of oxycodone (o.g., 10 mg/kg) alone, or together with lorcaserin (s.c., 2 mg/kg) (n = 7–10). Drug F[1,32] = 0.002, p >0.05 ; time, F[1,232] = 14.30, p < 0.001; interaction of drug and time, F[1,32] = 0.19, p > 0.05. Data were evaluated with a two-way ANOVA followed by Dunnett’s multiple comparison test. *p<0.05, ***p<0.001. n.s., not significant. Data are mean ± S.E.M